Jonathan Mark Sutton

This inventor holds 33 USPTO granted patents and 7 published patent applications and 4 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Chiesi Farmaceutici S.p.a., Asterand UK Limited, Cancer Research Technology Limited. Active years: 2007-2025.

USPTO Granted Patents = 33 (Patent Applications = 7)

% Patents Active = 60.6

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 62(Granted Patents)

Location History:

Essex, GB (2008)
Margate Kent, GB (2021)
Harlow, GB (2007 - 2023)

Company Filing History:

12 out of 340

Chiesi Farmaceutici S.p.a.

Cancer Research Technology Limited

Pharmagene Laboratories Limited

patents

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

Urolithin Derivatives

RET Inhibitors

Heterocyclic Compounds

Antibiotics

Pyrazolone Compounds

Neutrophil Elastase Inhibitors

Pyrimidinone Compounds

EP2 Receptor Agonists

Chemical Compounds

Kinase Inhibitors

Inhibition of Enzymes

Human Neutrophil Elastase

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473269 - Urolithin derivatives and methods of use thereof (2025-11-18),

2. 12358884 - Urolithin derivatives and methods of use thereof (2025-07-15),

3. 12351567 - Urolithin derivatives and methods of use thereof (2025-07-08),

4. 11820751 - Urolithin derivatives and methods of use thereof (2023-11-21),

5. 11680068 - Compounds useful as RET inhibitors (2023-06-20),

6. 11661423 - Heterocyclic compounds as RET kinase inhibitors (2023-05-30),

7. 11548896 - Heterocyclic compounds as RET kinase inhibitors (2023-01-10),

8. 11352361 - Compounds useful as RET inhibitors (2022-06-07),

9. 11000511 - Chemical compounds as antibiotics (2021-05-11),

10. 10954241 - Heterocyclic compounds as ret kinase inhibitors (2021-03-23),

11. 10844067 - Heterocyclic compounds as RET kinase inhibitors (2020-11-24),

12. 10172830 - Pyrazolone compounds having human neutrophil elastase inhibitory properties (2019-01-08),

13. 10023558 - Compounds (2018-07-17),

14. 9868740 - Pyrimidinone compounds which are HNE inhibitors (2018-01-16),

15. 9828382 - Pyrimidinone compounds as human neutrophil elastase inhibitors (2017-11-28),

Title: The Innovative Journey of Jonathan Mark Sutton: A Pioneer in Medical Treatments

Introduction: Meet Jonathan Mark Sutton, a prolific inventor hailing from Harlow, GB, with an impressive portfolio of 30 patents to his name.

Latest Patents: Among his recent inventions are groundbreaking compounds like Urolithin derivatives for treating neuronal and mitochondrial diseases, as well as RET inhibitors for combating proliferative disorders such as cancer. These patents showcase his commitment to advancing medical treatments.

Career Highlights: Throughout his career, Jonathan has made significant contributions while working at esteemed companies such as Chiesi Farmaceutici S.p.a. and Asterand UK Limited, where he played a key role in driving innovation and research in the pharmaceutical industry.

Collaborations: Jonathan has collaborated with talented individuals like George Hynd and Carmelida Capaldi, creating a dynamic and innovative work environment that has led to the development of revolutionary medical solutions.

Conclusion: Jonathan Mark Sutton's dedication to pushing the boundaries of medical science through his inventions and collaborations underscores his status as a pioneering inventor in the field. His impactful work continues to inspire innovation and progress in the realm of medical treatments.